$175.05
0.49% day before yesterday
NYSE, Apr 11, 10:12 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock price

$175.05
-38.54 18.04% 1M
-19.14 9.86% 6M
-2.65 1.49% YTD
+7.53 4.50% 1Y
+5.22 3.07% 3Y
+94.75 118.00% 5Y
+113.85 186.03% 10Y
NYSE, Closing price Fri, Apr 11 2025
+0.85 0.49%
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

Key metrics

Market capitalization $309.66b
Enterprise Value $371.98b
P/E (TTM) P/E ratio 73.19
EV/FCF (TTM) EV/FCF 20.86
EV/Sales (TTM) EV/Sales 6.60
P/S ratio (TTM) P/S ratio 5.50
P/B ratio (TTM) P/B ratio 92.93
Dividend yield 3.59%
Last dividend (FY24) $6.29
Revenue growth (TTM) Revenue growth 3.71%
Revenue (TTM) Revenue $56.33b
EBIT (operating result TTM) EBIT $12.15b
Free Cash Flow (TTM) Free Cash Flow $17.83b
Cash position $5.56b
EPS (TTM) EPS $2.39
P/E forward 25.19
P/S forward 5.20
EV/Sales forward 6.25
Short interest 1.11%
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a AbbVie forecast:

17x Buy
61%
10x Hold
36%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a AbbVie forecast:

Buy
61%
Hold
36%
Sell
4%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
56,334 56,334
4% 4%
100%
- Direct Costs 16,831 16,831
5% 5%
30%
39,503 39,503
3% 3%
70%
- Selling and Administrative Expenses 6,219 6,219
254% 254%
11%
- Research and Development Expense 12,791 12,791
67% 67%
23%
20,493 20,493
29% 29%
36%
- Depreciation and Amortization 8,344 8,344
4% 4%
15%
EBIT (Operating Income) EBIT 12,149 12,149
40% 40%
22%
Net Profit 4,238 4,238
12% 12%
8%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Negative
CNBC
one day ago
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Positive
Barrons
2 days ago
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Positive
CNBC
3 days ago
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today